Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg

International Journal of Psychiatry in Clinical Practice

Volumn 13, Issue 1, 2009, Pages 36-47

  Mauri, Massimo Carlo ^a,e   Turner, Martin ^b   Volonteri, Lucia S ^a   Medori, Rossella ^c   Maier, Wolfgang ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c Janssen Cilag EMEA Belgium   (Belgium)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Antipsychotic; Injectable; Long acting; Risperidone; Schizophrenia

Indexed keywords

RISPERIDONE;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 60749131650     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500802411979     Document Type: Article

References (41)

1. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patients Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10.
2. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.
3. Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001;16:57-63.
4. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadhrence in schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):3-8.
5. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(Suppl 16):14-7.
6. Herings RM, Erkens JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf 2003;12:423-4.
7. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-91.
8. Strasser O, Schmauss M, Messer T. Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication. Psychiatr Prax 2004;31(Suppl 1):S38-40.
9. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(Suppl 12):1-100.
10. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):9-14.
11. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-73.
12. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-9.
13. Tavcar R, Dernovsek Z, Zvan V. Choosing antipsychotic maintenance therapy - a naturalistic study. Pharmacopsychiatry 2000;33:66-71.
14. Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45:50-9.
15. Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-7.
16. Arango C, Bombín I, González-Salvador T, García-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006;21:34-40.
17. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85.
18. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219-25.
19. Csernansky JG, Mahmoud R, Brenner R. Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 2002;346:16-22.
20. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8.
21. Kissling W, Heres S, Lloyd K, Sacchetti E, Bouhours P, Medori R, et al. Direct transition to long-acting risperidone - analysis of long-term efficacy. J Psychopharmacol 2005;19(Suppl 5):15-21.
22. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-32.
23. Knox ED, Stimmel GL. Clinical review of long-acting, injectable formulation of risperidone. Clin Ther 2004;26:1994-2002.
24. Parellada E. Clinical experience and management considerations with long-acting risperidone. Curr Med Res Opin 2006;22:241-55.
25. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl 16):18-23.
26. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70:91-100.
27. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-7.
28. Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 2006;16:233-40.
29. Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-9.
30. Marder SR, Conley R, Ereshefsky L, Kane JM, Turner MS. Clinical guidelines: Dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003;64(Suppl 16):41-6.
31. Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. StoRMi Study Group. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005;20:121-30.
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
33. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
34. Guy W. Clinical Global Impression. In: ECDEU Assessment Manual for Psychopharmacology, vol. 76. Rockville, MD: US Department of Health, Education, and Welfare; 1976. p 218-20.
35. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
36. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESR). Schizophr Res 2005;76:247-65.
37. Lasser RA, Bossie CA, Gharabawi GM, Baldessarini RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005;8:427-38.
38. Viner MW, Matuszak JM, Knight LJ. Initial dosing strategies for long-acting injectable risperidone. J Clin Psychiatry 2006;67:1310-1.
39. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357-76.
40. Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006;67:1194-203.
41. Turner M. How to switch patients to long-acting risperidone from another antipsychotic; pp. 125-9. In: Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics. J Clin Psychiatry 2004;65:120-31.